At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 96 enrolled
Drug / intervention
Salbutamol +1 moredrug
Likely dose
Salbutamol 0,1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial
In Brief
A Phase 4 clinical trial evaluating Salbutamol and Norflouran (Placebo Evohaler(R) ) for Ventricular Septal Defect. Completed, enrolled 96 participants across 1 site.
Detailed Summary
The overall objective for this study is to test whether β2-agonists will affect the cardiopulmonary capacity of VSD-operated patients compared with un-operated VSD-patients and healthy age- and gender-matched controls.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVentricular Septal Defect
CountriesDenmark
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionJul 2017
Study CompletionJan 2018
TodayJul 2026
First PostedSep 26, 2016
Enrollment StartOct 15, 2016
Primary CompletionJul 1, 2017
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.8 years ago
Interventions
Salbutamoldrug
Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
Norflouran (Placebo Evohaler(R) )drug
Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.